Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Laboratorios Farmaceuticos Rovi SA (Rovi), a subsidiary of Norbel Inversiones SL, is a pharmaceutical company that research, develops, manufactures, and markets prescription and hospital products. The company's portfolio includes licensed prescription pharmaceuticals in the cardiovascular, osteoarticular, thrombosis, pulmonology, antibacterial, central nervous system (CNS), endocrinology, and urology therapeutic areas. It also offers contract development and manufacturing services. Rovi markets its products under its own and licensed brands, including Ameride, Bertanel, Enoxaparin Rovi, D3 Rovi, Exxiv, Prinivil, Rhodogil, Glufan, Hibor, Hirobriz, Breezhaler, Neparvis, and Mysimba. It operates in Portugal, Germany, the UK, Italy, France, and Poland. Rovi is headquartered in Madrid, Spain.
Headquarters
Spain
Address
C/ Julian Camarillo, 35, Madrid, 28037
Website
www.rovi.es
Telephone
34 91 0213000
No of Employees
2,232
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ROVI (MCE)
Revenue (2024)
$838.8M
-2.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
2.6%
(2024 vs 2023)
Market Cap*
$3.2B
Net Profit Margin (2024)
XYZ
5.4%
(2024 vs 2023)
* As of and is in US$
Laboratorios Farmaceuticos Rovi SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Prescription Medicines: | Contract Development and Manufacturing Services | Ameride |
| Cardiovascular Products | ENOXAPARIN ROVI | |
| Osteoarticular Products | D3 ROVI | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, ROVI Pharma Industrial Services, S.A.U. entered into an agreement with F. Hoffmann-La Roche Ltd. to manufacture a new drug belonging to Roche's metabolic and cardiovascular portfolio. |
| 2025 | Contracts/Agreements | In October, ROVI Pharma Industrial Services, S.A.U. partnered with F. Hoffmann-La Roche Ltd. to manufacture a clinical-stage metabolic/cardiovascular medicine, providing a high-speed filling line at its San Sebastian de los Reyes facility. |
| 2026 | Asset Purchase | In April, ROIS Phoenix Inc acquired a pharmaceutical manufacturing plant located in Phoenix, Arizona from Bristol Myers Squibb. |
Competitor Comparison
| Key Parameters | Laboratorios Farmaceuticos Rovi SA | Esteve Healthcare SL | Faes Farma SA | ASAC Compania De Biotecnologia E Investigacion SA | Bioiberica SAU |
|---|---|---|---|---|---|
| Headquarters | Spain | Spain | Spain | Spain | Spain |
| City | Madrid | Barcelona | Leioa | Alicante | Barcelona |
| State/Province | Madrid | Barcelona | Vizcaya | Alicante | Barcelona |
| No. of Employees | 2,232 | 2,223 | 2,671 | 400 | 450 |
| Entity Type | Public | Private | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Juan Lopez-Belmonte Lopez | Chief Executive Officer; Chairman; President | Executive Board | 2025 | - |
| Ivan Lopez-Belmonte Encina | Vice President; Deputy Chairman | Executive Board | 2025 | - |
| Javier Lopez-Belmonte Encina | Vice President; Deputy Chairman | Executive Board | 2025 | - |
| Gabriel Nunez Fernandez | Secretary | Senior Management | 2014 | - |
| Ignacio Zarzalejos Toledano | Deputy Secretary | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer